ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy
ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint
ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy
ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint